• SHOP
    • COMBOS
    • TESTIMONIALS
    • CART
    • INGREDIENTS
      • 2-DEOXY-D-GLUCOSE (2DG)
      • ACACIA CYANOPHYLLA FLOWER
      • ACORI GRAMINEI RHIZOMA
      • AEGLE MARMELOS CORREA
      • AGARICUS BLAZEI
      • AGED GARLIC EXTRACT
      • AFRAMOMUM MELEGUETA
      • ALOE ARBORESCENS
      • ALBIZIA
      • ALPINIA OFFICINARUM
      • ALTERNANTHERA SESSILIS
      • AMERICAN GINSENG
      • AMYGDALIN
      • ANACYCLUS PYRETHRUM
      • ANGELICA ARCHANGELICA
      • ANGELICA SINENSIS
      • ANTRODIA
      • APIGENIN
      • ARTICHOKE LEAF
      • ARTOCARPIN
      • AJUGA TURKESTANICA
      • ASHWAGANDHA
      • ASPALATHIN
      • ASTRAGALUS COMPLANATUS
      • AVENA SATIVA
      • BACOPA MONNIERI
      • BAVACHIN
      • BEE POLLEN
      • BETULINIC ACID
      • BOSWELLIC ACID
      • BREVILIN A
      • CAMPESTEROL
      • CAPSAICIN
      • CARCININE
      • CASTICIN
      • CHRYSIN
      • CIANIDANOL
      • CINNAMOMUM ZEYLANICUM
      • CITRULLUS COLOCYNTHIS
      • CITRUS RETICULATA PEEL
      • CODONOPSIS
      • CONJUGATED LINOLEIC ACID
      • COSTUNOLIDE
      • CYANIDIN
      • CUCURBITACIN D
      • DAIDZEIN
      • DECURSIN
      • DELPHINIDIN
      • DIGITALIS PURPREA (DIGOXIN)
      • DIOSMIN
      • ELLAGIC ACID
      • EMBELIN
      • ERIODICTYOL
      • GALLIC ACID
      • GLYCITEIN
      • GLYCYRRHIZIN
      • HYPERFORIN
      • ICARIIN
      • ISORHAMNETIN
      • ISOORIENTIN
      • ISOVITEXIN
      • JACEOSIDIN
      • KAEMPFEROL
      • KIGELIA AFRICANA
      • KURARINONE
      • LEMON BALM
      • LICORICIDIN
      • LIPOIC ACID
      • LUPEOL
      • MAGNOLOL
      • MULBERRY LEAF
      • NARINGENIN
      • NOBILETIN
      • OLEACEIN
      • OLEANOLIC ACID
      • OLIVE OIL
      • ORIDONIN
      • PARTHENOLIDE
      • PHLOROGLUCINOL
      • PHLORIZIN
      • PICEATANNOL
      • PRISTIMERIN
      • PROANTHOCYANIDINS
      • PROCYANIDIN B3
      • PSEUDOLARIC ACID B
      • PTEROSTILBENE
      • RUTIN
      • SOLIDAGO VIRGAUREA
      • TANGERETIN
      • TARAXASTEROL
      • TRICHOSTATIN A
      • WEDELOLACTONE
      • WOGONIN
      • YERBA MATE
    • ABOUT
    • SCIENTIFIC STUDIES
      • ADAPTOGENS
      • ADIPOCYTE APOPTOSIS (KILLING FAT CELLS)
      • ADDICTION AND THE BRAIN
      • ADDICTION & STRESS
      • ADDICTION WITHDRAWAL
      • ADIPOCYTE DEDIFFERENTIATION (THE REVERSAL OF FAT FORMATION)
      • ADIPOCYTE DIFFERENTIATION
      • ALLERGIES & CYTOKINES
      • ALDOSTERONE & OBESITY/HYPERTENSION
      • ALZHEIMER’S, DEMENTIA, PARKINSON’S
      • ANTI-ACNE EFFECT OF FLAVONOIDS AND POLYPHENOLS
      • ADVANCED GLYCATION END PRODUCTS (AGES)
      • ADDICTION TREATMENT
      • AMPK
      • ANTI AGING
      • ANTIAGING EFFECTS OF COFFEE
      • ANTI-AGING EFFECTS OF FLAVONOIDS & POLYPHENOLS
      • ANTI-APOPTOTIC PATHWAYS
      • ANTI ATHEROGENIC
      • ANTI-CANCER EFFECTS OF FLAVONOIDS & POLYPHENOLS
      • ANTI CARIOGENIC (Protecting From Tooth Decay)
      • ANTI COVID-19 EFFECTS OF MEDICINAL PLANTS, FLAVONOIDS & POLYPHENOLS
      • ANTI GLYCATIVE
      • ANTI GLYCATION AGENTS
      • ANTI-INFLAMMATORY EFFECTS OF FLAVONOIDS & POLYPHENOLS
      • ANTI-VIRAL EFFECTS OF FLAVONOIDS & POLYPHENOLS
      • ANTI WRINKLE AGENTS
      • APOPTOSIS
      • APOPTOSIS IN 3T3-L1
      • AUTOPHAGY
      • BCL-2
      • BCL-W
      • BCL-XL
      • BDNF
      • BECLIN-1 & AUTOPHAGY
      • BH3 MIMETICS
      • BIM aka BCL2L11
      • BMI-1
      • BRASSINOSTEROIDS
      • CALORIE RESTRICTION
      • CALORIE RESTRICTION & LIFESPAN EXTENSION
      • CARBAMYLATION
      • CARBONYL SCAVENGER
      • CARBONYL STRESS
      • CARDIOPROTECTIVE AGENTS
      • CARDIAC GLYCOSIDES
      • CATALASE
      • CELL CYCLE ARREST
      • CENTENARIANS
      • CHOLESTEROL EFFLUX
      • COGNITIVE ENHANCEMENT
      • COLD SHOCK PROTEINS
      • COLD-INDUCIBLE RNA-BINDING PROTEIN (CIRBP) & DNA REPAIR
      • CONDITIONED PLACE PREFERENCE
      • CORTICOTROPIN RELEASING FACTOR
      • CRYOTHERAPY
      • CRYOLIPOLYSIS: FREEZING FAT TO DEATH
      • CYP2E1
      • CYTOKINES IN PAIN, INFLAMMATION & AGING
      • DAF-16
      • DIABETES & CANCER
      • DIHYDROTESTOSTERONE (DHT)
      • DNA METHYLATION & AGING
      • DNA REPAIR
      • DNA REPAIR VIA FLAVONOIDS & POLYPHENOLS
      • ADDICTION & DOPAMINE
      • DRY FASTING AND FLUID RESTRICTION FASTING
      • DYNORPHIN
      • ELLAGITANNINS
      • ENLARGED HEART AND CARDIOMEGALY
      • EPIGENETIC MODIFIERS
      • EPINEPHRINE
      • ERGOGENIC AGENTS (INCREASE ATHLETIC PERFORMANCE)
      • EXCITOXICITY & THE BRAIN
      • EXTRACELLULAR MATRIX STIFFENING (10TH HALLMARK OF AGING)
      • EXTENDS LIFESPAN
      • EXTINCTION TRAINING
      • FASTING BRAIN
      • FASTING CANCER
      • FASTING & CANCER
      • FASTING MIMICKING DIET
      • FEAR EXTINCTION
      • FGF21
      • FLAVONES
      • GABA (γ-AMINOBUTYRIC ACID)
      • GALLOTANNINS
      • GLUCONEOGENESIS
      • GLUTAMATE & BRAIN
      • GLYCATION
      • KLOTHO
      • FASTING, CALORIE RESTRICTION & EXTENDING LIFESPAN
      • FOXO3
      • FOXO4
      • HALLMARKS OF AGING
      • HEPATOPROTECTIVE AGENTS (KEEPING LIVER HEALTHY)
      • HMGB1
      • HORMESIS
      • HPA AXIS
      • HSP70, THE ANTI-AGING PROTEIN
      • HSP90 INHIBITORS
      • HYPERGLYCEMIA
      • HYPERINSULINEMIA
      • HYPOACTIVE SEXUAL DESIRE (WHY PEOPLE HAVE ZERO SEX DRIVE)
      • HYPOCRETIN OREXIN
      • IKK
      • IL-6/STAT3
      • IRISIN
      • ISOFLAVONES
      • IMMUNOSENESCENCE
      • INCREASE PROTEIN SYNTHESIS
      • INFECTOBESITY
      • INFLAMMATION & ANXIETY
      • INFLAMMATION & CANCER
      • INFLAMMATION & DEPRESSION
      • INFLAMMATION & OBESITY
      • INFLAMMAGING
      • INHIBITION OF RENAL GLUCOSE REABSORPTION
      • INSULIN & AGING
      • INSULIN & CANCER: HOW INSULIN LITERALLY PROTECTS CANCER CELLS FROM BEING KILLED
      • INSULIN & MTOR
      • INSULIN & OBESITY
      • INTERMITTENT FASTING
      • JAK INHIBITION ALLEVIATES SASP
      • JNK ACTIVATION PREVENTS PREMATURE SENESCENCE
      • KETONE BODIES
      • KETOGENIC DIET
      • LEYDIG CELL STEROIDOGENESIS
      • LIFESPAN EXTENSION
      • LIPOLYTIC AGENTS
      • LIPID DROPLETS
      • LIPOLYSIS (THE DECOMPOSITION OF BODY FAT)
      • LOWERING CHOLESTEROL THRU FASTING, DIET & MEDICINAL PLANTS
      • MATRIX METALLOPROTEINASES (MMPs)
      • MCL-1
      • MDM2 INHIBITION AS SASP INHIBITOR
      • MEDITERRANEAN DIET
      • MENAQUINONE 4
      • METABOLIC REPROGRAMMING
      • METABOLIC SYNDROME EXTRACT
      • METHIONINE RESTRICTION
      • MITOCHONDRIAL UNCOUPLING
      • MONKEYPOX
      • MSG (MONOSOSODIUM GLUTAMATE)
      • MUSCLE FORCE PRODUCTION
      • MUSCLE ATROPHY (PREVENTING)
      • MYOGENESIS
      • MYOSTATIN INHIBITION
      • MYOSTATIN INHIBITION PRESERVES MUSCLE
      • mTORC2
      • mTOR: THE RAPID AGING PATHWAY
      • NATURAL ANTICOAGULANTS
      • NATURAL AROMATASE INHIBITORS
      • NEUROGENESIS (GROWING NEW BRAIN CELLS)
      • NEUROCHEMISTRY OF ADDICTION
      • NEUROPLASTICITY
      • NEUROINFLAMMATION
      • NEUROPROTECTIVE AGENTS
      • NMDA & ANXIETY & DEPRESSION
      • NMDA RECEPTOR AND FEAR
      • NON-OPIOID ANALGESICS (PLANT BASED)
      • NOOTROPICS
      • NORADRENERGIC
      • NOREPINEPHRINE
      • NRF2: MASTER REGULATOR OF THE AGING PROCESS
      • NF-KB
      • ONCOGENE ACTIVATION INDUCED SENESCENCE
      • OVERNUTRITION
      • OXIDATIVE STRESS & AGING
      • P16INK4A
      • P38MAPK
      • P53: TUMOR SUPRESSOR
      • PERIODONTITIS
      • PHYTOCHEMICALS
      • PHYTOSTEROLS
      • PHYTOSTANOLS
      • PHYTOECDYSTEROIDS
      • PROANTHOCYANIDINS
      • PROTEIN CARBONYLATION
      • POLYAMINES & THEIR EFFECT ON BRAIN (NMDA, DEPRESSION, SUICIDE RISK)
      • PPARY2
      • PREMATURE SENESCENCE
      • PREVENTING SKIN AGING
      • PUFAS
      • PURGATIVES
      • RAPAMYCIN (MTOR INHIBITION)
      • RECEPTOR “Κ OPIOID”
      • RED WINE
      • RENAL (KIDNEY) PROTECTIVE AGENTS
      • REMINERALIZATION OF TEETH
      • REPAIR OF DNA BREAKS “DOUBLE STRAND”
      • RESTORE INSULIN SENSITIVITY
      • SASP & ADIPOSE TISSUE
      • SENESCENT CELLS, SASP & SENOLYTICS
      • SENESCENCE-BETA-GALACTOSIDASE (SA-β-gal or SABG)
      • SGLT2 INHIBITORS
      • SGLT2 INHIBITION FOR LIFESPAN EXTENSION
      • SHBG
      • SIRT1
      • SKELETAL MUSCLE HYPERTROPHY (THE SCIENCE OF BUILDING MUSCLE)
      • SKIN ELASTICITY
      • SKIN PHOTOAGING (Preventing & Repairing)
      • SLEEP DEPRIVATION AS THERAPY FOR DEPRESSION
      • SIRT1 & LONGEVITY
      • SMALLPOX
      • SUGAR & AGING
      • STAR PROTEIN
      • STAT3
      • STEM CELL EXHAUSTION
      • STEM CELL REGENERATION
      • STEM CELL THERAPY
      • STIMULATED LIPOLYSYS
      • STEROIDOGENESIS (THE PRODUCTION OF HORMONES IN BODY)
      • STREPTOCOCCUS MUTANS (MAIN BACTERIA BEHIND TOOTH DECAY)
      • STRESS & AGING
      • STRESS & THE BRAIN
      • TELOMERE SHORTENING & PREMATURE AGING
      • TIME RESTRICTED FEEDING
      • TRAUMATIC BRAIN INJURY (HEALING)
      • TRYPTOPHAN HYDROXYLASE 2
      • VISCERAL ADIPOSITY
    • HOME
    • CONTACT
    • INTERSTELLAR 88/8: EXTREME WEIGHTLOSS PROTOCOL
    • The Ultimate Dry Fasting Resource
    0
    Mcl-1
    January 31, 2020
    Senescence-associated beta-galactosidase (SA-β-gal or SABG)
    February 10, 2020

    Neuroprotective effects of flavonoids and polyphenols

     

    1. A berry thought-provoking idea: the potential role of plant polyphenols in the treatment of age-related cognitive disorders
    2. A bird’s-eye view of the multiple biochemical mechanisms that propel pathology of Alzheimer’s disease: recent advances and mechanistic perspectives on …
    3. A blueberry extract-supplemented diet rescues phenotypes in drosophila melanogaster models of parkinson disease
    4. A Comparative Study on the Phenolic Composition and Biological Activities of Morus alba L. Commercial Samples
    5. A Comparison of the Antioxidant Activity with the Total Phenolic and Total flavonoid contents of the Leaves and Stem-bark of Anogeissus leiocarpa (DC.) Guill& Pirr …
    6. A comprehensive database and analysis framework to incorporate multiscale data types and enable integrated analysis of bioactive polyphenols
    7. A comprehensive review on phytochemistry, pharmacology, and flavonoid biosynthesis of Scutellaria baicalensis
    8. A Current Understanding of Alzheimer’s Disease and the Prospects of Phytopharmacological Intervention as a Management Strategy
    9. A meta-analysis of tea drinking and risk of Parkinson’s disease
    10. A molecular approach in drug development for Alzheimer’s disease
    11. A Narrative Review of Lifestyle Factors Associated with Parkinson’s Disease Risk and Progression
    12. A Novel GSK3β Inhibitor Reduces Tau Pathology in Alzheimer’s Disease
    13. A Paradigm Shift to Prevent and Treat Alzheimer’s Disease: From Monotargeting Pharmaceuticals to Pleiotropic Plant Polyphenols
    14. A pharmacological appraisal of neuroprotective and neurorestorative flavonoids against Neurodegenerative diseases
    15. A review of antioxidant and pharmacological properties of phenolic compounds in Acacia confusa
    16. A Review of Antioxidants and Alzheimer
    17. A review of antioxidants and Alzheimer’s disease
    18. A review of genome mutation and Alzheimer’s disease
    19. A review on cholinesterase inhibitors for Alzheimer’s disease
    20. A Review on Current Strategies and Future Perspective in Respect to Alzheimer’s Disease Treatment
    21. A review on iron chelators as potential therapeutic agents for the treatment of Alzheimer’s and Parkinson’s diseases
    22. A Review on Medicinal Plants for Alzheimer’s disease
    23. A review on mitochondrial restorative mechanism of antioxidants in Alzheimer’s disease and other neurological conditions
    24. A review on potential mechanisms of Terminalia chebula in Alzheimer’s disease
    25. A review on tacrine-based scaffolds as multi-target drugs (MTDLs) for Alzheimer’s disease
    26. A review on the beneficial effects of tea polyphenols on human health
    27. A review on the status of the phenolic compounds and antioxidant capacity of the flour: Effects of cereal processing
    28. A review–probable mechanism of action of curcumin for the treatment of Alzheimer disease (AD)
    29. A review: inflammatory process in Alzheimer’s disease, role of cytokines
    30. A small molecule ApoE4-targeted therapeutic candidate that normalizes sirtuin 1 levels and improves cognition in an Alzheimer’s disease mouse model
    31. A Study on the Role of Mimosa Pudica (Thottar Chinungi) on the Experimental Models of Parkinsonism (Nadukku Vatham)
    32. A synopsis on the linkage between age-related dementias and vascular disorders
    33. A systematic review on the role of natural products in modulating the pathways in Alzheimer’s disease
    34. Acacetin—A simple flavone exhibiting diverse pharmacological activities
    35. Accumulation of citrus flavanones in bovine milk following citrus pulp incorporation into the diet of dairy cows
    36. Acetyl-cholinesterase Inhibition by Extracts and Isolated Flavones from Linaria reflexa Desf. (Scrophulariaceae)
    37. Acetylated flavonoid Glycosides Potentiating NGF Action from Scoparia dulcis
    38. Activation of pro‐survival Akt and ERK1/2 signalling pathways underlie the anti‐apoptotic effects of flavanones in cortical neurons
    39. Acute effects of flavonoid-rich blueberry on cognitive and vascular function in healthy older adults
    40. Adult‐onset brain tumors and neurodegeneration: Are polyphenols protective?
    41. Advancement of multi-target drug discoveries and promising applications in the field of Alzheimer’s disease
    42. Advances in multi-functional ligands and the need for metal-related pharmacology for the management of Alzheimer disease
    43. Advances in research on active constituents of Chinese materia medica in treatment of Alzheimer’s disease [J]
    44. Agathisflavone, a flavonoid derived from Poincianella pyramidalis (Tul.), enhances neuronal population and protects against glutamate excitotoxicity
    45. Age-related cognitive impairment as a sign of geriatric neurocardiovascular interactions: may polyphenols play a protective role?
    46. Aging risk factors and Parkinson’s disease: contrasting roles of common dietary constituents
    47. Alcohol Consumption in Predementia and dementia Syndromes
    48. Alcohol intake and risk of dementia
    49. Alcohol, wine and mental health: focus on dementia and stroke
    50. Alcoholic beverages and incidence of dementia: 34-year follow-up of the prospective population study of women in Göteborg
    51. Almond, hazelnut and walnut, three nuts for neuroprotection in Alzheimer’s disease: A neuropharmacological review of their bioactive constituents
    52. Alpha-secretase ADAM10 regulation: insights into Alzheimer’s disease treatment
    53. Alpha-Synuclein and synuceinopathies as related to Parkinson’s disease
    54. Alpha-synuclein oligomers—neurotoxic molecules in Parkinson’s disease and other Lewy body disorders
    55. Altered Micro-RNA Regulation and Neuroprotection Activity of Eremostachys labiosiformis in Alzheimer’s Disease Model
    56. Alzheimer’s and Parkinson’s Disease Novel Therapeutic Target: The Mitochondrial Pyruvate Carrier-Ligand Docking to Screen Natural Compounds Related to Classic …
    57. Alzheimer’s Dementia: Can It Be Prevented?
    58. Alzheimer’s disease (AD) genes: Enrichment in cancer genes and those related to comorbid conditions, risk factors (pollution and pathogens) or beneficial agents …
    59. Alzheimer’s Disease & Treatment
    60. Alzheimer’s Disease & Treatment
    61. Alzheimer’s Disease & Treatment
    62. Alzheimer’s Disease & Treatment, Vol. 1
    63. Alzheimer’s disease and antioxidant therapy: how long how far?
    64. Alzheimer’s disease and its current treatments; Is there a possibility for a cure
    65. Alzheimer’s Disease and Metal Contamination: Aspects on Genotoxicity
    66. Alzheimer’s disease and natural products: Future regimens emerging from nature
    67. Alzheimer’s disease and other Neurodegenerative disorders
    68. Alzheimer’s Disease and Oxidative Stress
    69. Alzheimer’s Disease and Parkinson’s Disease: A Nutritional Toxicology Perspective of the Impact of Oxidative Stress, Mitochondrial Dysfunction, Nutrigenomics and …
    70. Alzheimer’s Disease and the Main Aspects-Literature Review
    71. Alzheimer’s DISEASE AND THE MICROBIOME
    72. Alzheimer’s disease as oligomeropathy
    73. Alzheimer’s Disease Pharmacotherapy in Relation to Cholinergic System Involvement
    74. Alzheimer’s Disease Theranostics
    75. Alzheimer’s disease, amnestic mild cognitive impairment, and age-associated memory impairment: current understanding and progress toward integrative prevention.
    76. Alzheimer’s Disease, Drosophila melanogaster and Polyphenols
    77. Alzheimer’s disease, neuroinflammation and the influence of different combinations of nutrients
    78. Alzheimer’s disease: A challenge in managing with certain medicinal plants-Areview
    79. Alzheimer’s disease: a journey from amyloid peptides and oxidative stress, to biomarker technologies and disease prevention strategies—gains from AIBL …
    80. Alzheimer’s Disease: An Approach for Non-Pharmacological Therapies
    81. Alzheimer’s disease: biological aspects, therapeutic perspectives and diagnostic tools
    82. Alzheimer’s Disease: Early Diagnosis & Fundamental Therapeutics
    83. Alzheimer’s disease: from pathology to therapeutic approaches
    84. Alzheimer’s disease: redox dysregulation as a common denominator for diverse pathogenic mechanisms
    85. Alzheimer’s disease: the pros and cons of pharmaceutical, nutritional, botanical, and stimulatory therapies, with a discussion of treatment strategies from the …
    86. Alzheimers Disease & Parkinsonism
    87. Ameliorating effect of ethanol leaf extract of Ficus hispida Linn. on amyloid beta Aβ (25-35) induced cognitive deficits and oxidative stress in Alzheimer’s mice
    88. Amelioration of 6-Hydroxydopamine-Lesion Induced Neurotoxicity by Different Extracts of Ocimum sanctum Leaves in Rodent Model of Parkinson’s Disease
    89. Amelioration of cognitive impairment and neurodegeneration by catechin hydrate in rat model of streptozotocin-induced experimental dementia of Alzheimer’s type
    90. Amentoflavone Ameliorates Aβ1–42-Induced Memory Deficits and oxidative stress in Cellular and Rat Model
    91. Amentoflavone protects dopaminergic neurons in MPTP-induced Parkinson’s disease model mice through PI3K/Akt and ERK signaling pathways
    92. Amentoflavone suppresses amyloid β1–42 neurotoxicity in Alzheimer’s disease through the inhibition of pyroptosis
    93. AMP‐activated protein kinase: a potential player in Alzheimer’s disease
    94. Amyloid A-Beta Peptide: In-Cell Studies and Mechanism of Polyphenol-Based Inhibition to Aggregation
    95. Amyloid precursor protein‐mediated free radicals and oxidative damage: Implications for the development and progression of Alzheimer’s disease
    96. Amyloid β-Peptide (1–42)-Induced oxidative stress in Alzheimer Disease: Importance in Disease Pathogenesis and Progression
    97. Amyloid β-protein assembly as a therapeutic target of Alzheimer’s disease
    98. Amyloid‐β deposition in Alzheimer transgenic mice is associated with oxidative stress
    99. An alternative approach to drug discovery for Alzheimer’s disease dementia
    100. An Evaluation of Cholesterol-lowering Effect of Soy Protein and Isoflavones on Postmenopausal Women and Hypercholesterolemic Humans.
    101. An Overview of Parkinson’s Disease and Oxidative Stress: Herbal Scenario
    102. An overview of the possible therapeutic role of SUMOylation in the treatment of Alzheimer’s disease
    103. An overview on global trends in nanotechnological approaches for Alzheimer therapy
    104. An overview on potential neuroprotective compounds for management of Alzheimer’s disease
    105. An overview on therapeutics attenuating amyloid β level in Alzheimer’s disease: Targeting neurotransmission, inflammation, oxidative stress and enhanced …
    106. An update on plant-originated treatment for Alzheimer’s disease
    107. An updated review on Anti-Alzheimer’s herbal drugs
    108. Analgesic and acetylcholinesterase inhibition potential of polyphenols from Scolopia crenata (Flacourtiaceae): An endemic medicinal plant of India
    109. Analysis of amino acid and phenolic content in honey by UPLC-ESI-MS/MS
    110. Analysis of technological developments in the treatment of Alzheimer’s disease through patent documents
    111. Anatomic and Disease Specificity of NADH CoQ1 Reductase (Complex I) Deficiency in Parkinson’s Disease
    112. Anesthesia Implications of the Use of Essential Oils in Alzheimer’s Dementia
    113. Animal models of Parkinson’s disease: a gateway to therapeutics?
    114. Anthocyanins Potentially Contribute to Defense against Alzheimer’s Disease
    115. Anthocyanins restore behavioral and biochemical changes caused by streptozotocin-induced sporadic dementia of Alzheimer’s type
    116. Anti-acetylcholinesterase and antioxidant activities and HPLC-MS analysis of polyphenol from extracts of Nelsonia canescens (Lam.) Spreng.
    117. Anti-adipogenic Effect of a Dietary flavonoid Fisetin in 3T3-L1 Cells
    118. Anti-aging and anti-aggregation properties of polyphenolic compounds in C. elegans
    119. Anti-Alzheimer potential of Green Moong Bean
    120. Anti-Alzheimer’s studies on β-sitosterol isolated from Polygonum hydropiper L.
    121. Anti-amnesic Effect of Leea indica Extract in Scopolamine-induced Amnesia of Alzheimer’s Type in Rats
    122. Anti-amyloidogenic activity of tannic acid and its activity to destabilize Alzheimer’s β-amyloid fibrils in vitro
    123. Anti-amyloidogenic effects of antioxidants: implications for the prevention and therapeutics of Alzheimer’s disease
    124. Anti-amyloidogenic properties of some phenolic compounds
    125. Anti-Demential Effect of EGB 761 on dementia Induced Wistar Rats
    126. Anti-Inflammatory Agents in Parkinson’s Disease
    127. Anti-inflammatory and immune therapy for Alzheimer’s disease: current status and future directions
    128. Anti-inflammatory and immunomodulatory properties of dietary flavonoids
    129. Anti-inflammatory Effects of flavonoid Compounds on TNBS-induced Acute Colitis in Rats
    130. Anti-inflammatory effects of flavonoids in Neurodegenerative disorders
    131. Anti-inflammatory Effects of O-methylated Flavonoid
    132. Anti-inflammatory, anti-diabetic, and anti-Alzheimer’s effects of prenylated flavonoids from Okinawa propolis: an investigation by experimental and computational …
    133. Anti-inflammatory, immunomodulatory, and prebiotic properties of dietary flavonoids
    134. Anti-neuroinflammatory potential of natural products in attenuation of Alzheimer’s disease
    135. Anti-Parkinson potential of silymarin: mechanistic insight and therapeutic standing
    136. Anti-Parkinsonian drug discovery from herbal medicines: what have we got from neurotoxic models?
    137. Antiaging Interventions: An Insight into Polyphenols and Brain Aging
    138. Antiapoptotic role of Agaricus blazei extract in rodent model of Parkinson’s disease
    139. Antidementic activity of Brassica oleracea l. var. Italica (brassicaceae) flower on memory deficit in young male rats
    140. Antidepressant flavonoids and their relationship with oxidative stress
    141. Antihepatotoxic, nephroprotective, and antioxidant activities of phenolic compounds from Satureja macrostema leaves against carbon tetrachloride-induced hepatic …
    142. Antioxidant activity and total phenolic content of ethanolic extract of Caesalpinia bonducella seeds
    143. Antioxidant activity of selected phenols estimated by ABTS and FRAP methods.
    144. Antioxidant Activity of Wine Polyphenols for Alzheimer Prevention
    145. Antioxidant and anti‐inflammatory properties of the citrus flavonoids hesperidin and hesperetin: an updated review of their molecular mechanisms and experimental …
    146. Antioxidant and Anticholinesterase Activities of Macrosphyra Longistyla (DC) Hiern Relevant in the Management of Alzheimer’s Disease
    147. Antioxidant and Choline Esterase Inhibitory Activity of Phenolic Rich Extracts from Bombax ceiba L. Flowers.
    148. Antioxidant and neuroprotective Effects of Synthetic Curcumin Analogues and Natural Phenolics
    149. Antioxidant and neuroprotective properties of blueberry polyphenols: a critical review
    150. Antioxidant and pro-oxidant effects of polyphenolic compounds and structure-activity relationship evidence
    151. Antioxidant Capacity and Behavioral Relevance of a Polyphenolic Extract of Chrysanthellum americanum in a Rat Model of Irritable Bowel Syndrome
    152. Antioxidant Capacity is Decreased in Alzheimer’s Disease and Mild Cognitive Impairment Patients
    153. ANTIOXIDANT EFFECT OF flavonoids IN Neurodegenerative DISEASES.
    154. Antioxidant effect of flavonoids present in Euterpe oleracea Martius and Neurodegenerative diseases: A literature review
    155. Antioxidant neuroprotection in Alzheimer’s disease as preventive and therapeutic approach
    156. Antioxidant Nutraceuticals and Parkinson’s Disease
    157. Antioxidant phenolic constituents from Parthenocissus tricuspidata
    158. Antioxidant plant polyphenols and cognitive disorders
    159. ANTIOXIDANT PROPERTIES OF A Ginkgo biloba LEAF EXTRACT (EGb 761) IN ANIMAL MODELS OF Alzheimer’s AND Parkinson’s DISEASES.
    160. Antioxidant properties of Crocus sativus L. and its constituents and relevance to Neurodegenerative diseases; focus on Alzheimer’s and Parkinson’s disease
    161. Antioxidant properties of natural polyphenols and their therapeutic potentials for Alzheimer’s disease
    162. Antioxidant therapy in Alzheimer’s disease: theory and practice
    163. Antioxidants and Alzheimer’s disease: from bench to bedside (and back again)
    164. Antioxidants and dementia risk: consideration through a cerebrovascular perspective
    165. Antioxidants as a potential therapy against age-related Neurodegenerative diseases: amyloid beta toxicity and Alzheimer’s disease
    166. Antioxidants in the Prevention and Treatment of Alzheimer’s Disease
    167. Antioxidants, diet, polyphenols and dementia
    168. Apolipoprotein ε-4 as a genetic determinant of Alzheimer’s disease heterogeneity
    169. Apples and their products effect on neurodegeneration and Alzheimer’s disease
    170. Application of yeast to study the tau and amyloid-β abnormalities of Alzheimer’s disease
    171. Applying Epigenetics to Alzheimer’s Disease via the Latent Early–life Associated Regulation (LEARn) Model
    172. Applying transcriptomic and proteomic knowledge to Parkinson’s disease drug discovery
    173. Approaches Based on Cholinergic Hypothesis and Cholinesterase Inhibitors in the Treatment of Alzheimer’s Disease
    174. Are polyphenols strong dietary agents against neurotoxicity and neurodegeneration?
    175. Arecanut (Areca catechu L) decreases Alzheimer’s disease symptoms: Compilation of research works
    176. Artemisia amygdalina Upregulates Nrf2 and Protects Neurons Against oxidative stress in Alzheimer Disease
    177. Asparagus cochinchinensis stimulates release of nerve growth factor and abrogates oxidative stress in the Tg2576 model for Alzheimer’s disease
    178. Assessment of anticholinesterase activities and antioxidant potentials of Anisomeles indica relevant to the treatment of Alzheimer’s disease
    179. Assessment of the effect of selected African plants on an in vitro model of Parkinson’s disease
    180. association of tea consumption with risk of Alzheimer’s disease and anti-beta-amyloid effects of tea
    181. ATR-IR study of the mechanism of aluminum chloride induced Alzheimer’s disease; curative and protective effect of Lipidium sativum water extract on …
    182. Attention-deficit/hyperactivity disorder–unifying mechanism involving antioxidant therapy: Phenolics, reactive oxygen species, and oxidative stress
    183. Attenuation of iNOS and COX2 by blueberry polyphenols is mediated through the suppression of NF-κB activation
    184. Auraptene Mitigates Parkinson’s Disease-Like Behavior by Protecting Inhibition of Mitochondrial Respiration and Scavenging Reactive Oxygen Species
    185. Autophagy in Alzheimer’s disease and promising modulatory effects of herbal medicine
    186. Autophagy, polyphenols and healthy ageing
    187. Aβ propagation and strains: implications for the phenotypic diversity in Alzheimer’s disease
    188. BACE inhibitors as potential therapeutics for Alzheimer’s disease
    189. BACE1 (β-secretase) inhibitors for the treatment of Alzheimer’s disease
    190. Baicalein reduces β‐amyloid and promotes nonamyloidogenic amyloid precursor protein processing in an Alzheimer’s disease transgenic mouse model
    191. Basal lipid peroxidation in substantia nigra is increased in Parkinson’s disease
    192. Behavioral and neurochemical alterations induced by vanillin in a mouse model of Alzheimer’s disease
    193. Beneficial effect of flavone derivatives on Aβ-induced memory deficit is mediated by peroxisome proliferator-activated receptor γ coactivator 1α: a comparative study
    194. Beneficial effect of the flavonoid luteolin on neuroinflammation
    195. Beneficial effects of flavonoids against Parkinson’s disease
    196. Beneficial Effects of flavonoids on Neurological Disorders
    197. Beneficial effects of n-3 polyunsaturated fatty acids administration in a partial lesion model of Parkinson’s disease: the role of glia and NRf2 regulation
    198. Beneficial effects of natural phenolics on levodopa methylation and oxidative neurodegeneration
    199. Beneficial effects of phenolic compounds from fruit and vegetables in Neurodegenerative diseases
    200. Beneficial effects of polyphenols on chronic diseases and ageing
    201. Beneficial properties of natural phenols: highlight on protection against pathological conditions associated with amyloid aggregation
    202. Benefits from dietary polyphenols for brain aging and Alzheimer’s disease
    203. Berry phenolics and their antioxidant activity
    204. Beta amyloid aggregation inhibitors: small molecules as candidate drugs for therapy of Alzheimer’s disease
    205. Beyond antioxidants: the cellular and molecular interactions of flavonoids and how these underpin their actions on the brain
    206. Biflavonoids as potential small molecule therapeutics for Alzheimer’s disease
    207. Bioactive composition and promising health benefits of natural food flavors and colorants: potential beyond their basic functions
    208. Bioactive flavonoids and Catechols as Hif1 and Nrf2 Protein Stabilizers-Implications for Parkinson’s Disease
    209. Bioactivity of olive oil phenols in neuroprotection
    210. Bioanalytical Approach to the Interaction of Novel sym-Triazine Derivatives with Alzheimer’s Disease Biomarkers
    211. Bioanalytical Approaches to Investigate Antioxidant Molecules and Nucleic Acid-Protein Interactions in Alzheimer’s Disease
    212. Bioavailability and activity of phytosome complexes from botanical polyphenols: the silymarin, curcumin, green tea, and grape seed extracts
    213. Bioavailability and pharmaco-therapeutic potential of luteolin in overcoming Alzheimer’s disease
    214. Bioavailability of dietary polyphenols: Factors contributing to their clinical application in CNS diseases
    215. Bioavailability, bioactivity and impact on health of dietary flavonoids and related compounds: an update
    216. Biochanin-A ameliorates behavioural and neurochemical derangements in cognitive-deficit mice for the betterment of Alzheimer’s disease
    217. Biochemical and therapeutic effects of antioxidants in the treatment of Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis
    218. Biological reactivity of polyphenolic− glutathione conjugates
    219. Biopharmaceutical Monotargeting versus ‘Universal Targeting’of Late-Onset Alzheimer’s Disease Using Mixtures of Pleiotropic Natural Compounds
    220. Biophenols pharmacology against the amyloidogenic activity in Alzheimer’s disease
    221. Biophenols: Enzymes (β-secretase, Cholinesterases, histone deacetylase and tyrosinase) inhibitors from olive (Olea europaea L.)
    222. Biophysical characteristics of proteins and living cells exposed to the green tea polyphenol epigallocatechin-3-gallate (EGCg): review of recent advances from …
    223. Bioprocessing Strategies to Enhance L-DOPA and Phenolic Bioactives in the Fava Bean (Vicia Faba)
    224. Biosynthesized metal nanoparticles as potential Alzheimer’s disease therapeutics
    225. Black tea theaflavins inhibit formation of toxic amyloid-β and α-synuclein fibrils
    226. Blanching alters the phenolic constituents and in vitro antioxidant and anticholinesterases properties of fireweed (Crassocephalum crepidioides)
    227. Blueberry polyhphenols and neuroprotection
    228. Blueberry polyphenols and neuroprotection
    229. Botanical phenolics and brain health
    230. Botanics: a potential source of new therapies for Alzheimer’s disease
    231. Brahmi (Bacopa monnieri): An ayurvedic herb against the Alzheimer’s disease
    232. Brain food for Alzheimer-free ageing: focus on herbal medicines
    233. Brain insulin resistance and deficiency as therapeutic targets in Alzheimer’s disease
    234. Brain iron accumulation in Parkinson’s disease: An investigation of genes related to iron metabolism and homeostasis and dietary behavior data in a case …
    235. Brain iron metabolism dysfunction in Parkinson’s disease
    236. Brain mitochondrial dysfunction in aging, neurodegeneration, and Parkinson’s disease
    237. C0550 Neuroinflammation in Alzheimer’s Disease: The Preventive and Therapeutic Potential of Polyphenolic Nutraceuticals
    238. Caffeic acid attenuates oxidative stress, learning and memory deficit in intra-cerebroventricular streptozotocin induced experimental dementia in rats
    239. Can co-activation of Nrf2 and neurotrophic signaling pathway slow Alzheimer’s disease?
    240. Can consuming flavonoids restore old microglia to their youthful state?
    241. Can we prevent Parkinson’s disease
    242. Cannabis Flavonoids—Antioxidant & Anti-Inflammatory Benefits
    243. Carbohydrates and Glycomimetics in Alzheimer’s Disease Therapeutics and Diagnosis
    244. Carbon nanomaterials and amyloid beta interactions: Possible potentials in the detection and treatment of Alzheimer’s disease
    245. Catechin polyphenols: neurodegeneration and neuroprotection in Neurodegenerative diseases
    246. Cell signaling pathways and iron chelation in the neurorestorative activity of green tea polyphenols: special reference to epigallocatechin gallate (EGCG)
    247. Cell signaling pathways in the neuroprotective actions of the green tea polyphenol (‐)‐epigallocatechin‐3‐gallate: implications for Neurodegenerative diseases
    248. Cellular and molecular aspects of Parkinson treatment: future therapeutic perspectives
    249. Cellular and molecular mechanisms of antioxidants in Parkinson’s disease
    250. Cellular phenotypes as inflammatory mediators in Parkinson’s disease: interventional targets and role of natural products
    251. Cerebral area differential redox response of neonatal rats to selenite-induced oxidative stress and to concurrent administration of highbush blueberry leaf polyphenols
    252. Cerebral hypoperfusion and glucose hypometabolism: key pathophysiological modulators promote neurodegeneration, cognitive impairment, and Alzheimer’s …
    253. Challenges for research on polyphenols from foods in Alzheimer’s disease: bioavailability, metabolism, and cellular and molecular mechanisms
    254. Champagne wine polyphenols protect primary cortical neurons against peroxynitrite-induced injury
    255. Changing paradigm from one target one ligand towards multi-target directed ligand design for key drug targets of Alzheimer disease: an important role of in silico …
    256. Characterization of Copper Interactions with Alzheimer Amyloid β Peptides: Identification of an Attomolar‐Affinity Copper Binding Site on Amyloid β1‐42
    257. Characterization of Copper Interactions with Alzheimer Amyloid β Peptides: Identification of an Attomolar‐Affinity Copper Binding Site on Amyloid β1‐42
    258. Characterization of neurotoxic effects of NMDA and the novel neuroprotection by phytopolyphenols in mice.
    259. Characterization of phenolic compounds using UPLC–HRMS and HPLC–DAD and anti-cholinesterase and anti-oxidant activities of Trifolium repens L. leaves
    260. CHARACTERIZATION OF THE neuroprotective ACTIVITY OF THE polyphenol (-)-EPIGALLOCATECHIN-3-GALLATE IN THE BRAIN
    261. Charnoly body as a novel biomarker of nutritional stress in Alzheimer’s Disease
    262. Chemical fingerprint of Bacopa monnieri L. and Rosmarinus officinalis L. and their neuroprotective activity against Alzheimer’s disease in rat model’s putative …
    263. Chemical structures, bioactivities and molecular mechanisms of citrus polymethoxyflavones
    264. Chinese herbs and herbal extracts for neuroprotection of dopaminergic neurons and potential therapeutic treatment of Parkinson’s disease
    265. Chocolate and the brain: neurobiological impact of cocoa flavanols on cognition and behavior
    266. Chocolate/Cocoa Polyphenols and Oxidative Stress
    267. Cholinesterase inhibitors as Alzheimer’s therapeutics
    268. Chroman-like cyclic prenylflavonoids promote neuronal differentiation and neurite outgrowth and are neuroprotective
    269. Chronic dietary supplementation of 4% figs on the modification of oxidative stress in Alzheimer’s disease transgenic mouse model
    270. Chronic Hypoxia Alters mRNA Expression of the Genes Related to Alzheimer’s Disease in Primary Neuronal Cells
    271. Chronic neuroinflammation in Alzheimer’s disease: new perspectives on animal models and promising candidate drugs
    272. Chronic treatment with resveratrol, a natural polyphenol found in grapes, alleviates oxidative stress and apoptotic cell death in ovariectomized female rats subjected to …
    273. Cinnamon, a promising prospect towards Alzheimer’s disease
    274. Citrus Fruit Polyphenols and Flavonoids: Applications to Psychiatric Disorders
    275. Clinical benefit and preservation of flavonols in dark chocolate manufacturing
    276. Clinical Development of a Novel Parkinsonian Drug in USA
    277. Cocoa and dark chocolate polyphenols: from biology to clinical applications
    278. Cocoa flavanols, exercise and the brain
    279. Cocoa Powder Triggers neuroprotective and Preventive Effects in a Human Alzheimer 0 s Disease Model by Modulating BDNF Signaling Pathway
    280. Cocoa powder triggers neuroprotective and preventive effects in a human Alzheimer’s disease model by modulating BDNF signaling pathway
    281. Coffee phenolic phytochemicals and kaempferol protect against oxidative damage of neuronal cells and memory impairments
    282. Coffee, tea, and caffeine consumption and prevention of late-life cognitive decline and dementia: a systematic review
    283. Cognitive Function and Consumption of Fruit and Vegetable Polyphenols in a Young Population: Is There a Relationship?
    284. Cognitive stimulation with leisure activities for prevention of cognitive decline and dementia: The aktiva study
    285. Cognitive-enhancing effect of quercetin in a rat model of Parkinson’s disease induced by 6-hydroxydopamine
    286. Combating oxidative stress disorders with citrus flavonoid: Naringenin
    287. Combination of EPA with carotenoids and polyphenol synergistically attenuated the transformation of microglia to M1 phenotype via inhibition of NF-κB
    288. Commentary: The flavonoid Baicalein Rescues Synaptic Plasticity and Memory Deficits in a Mouse Model of Alzheimer’s Disease
    289. Comparative analysis of total phenolic and total flavonoid contents, rutin, tannins and antioxidant capacity in Apiaceae and Lamiaceae families
    290. Comparative antioxidant activity of twenty traditional Indian medicinal plants and its correlation with total flavonoid and phenolic content
    291. Comparative evaluation of Helichrysi flos herbal extracts as dietary sources of plant polyphenols, and macro-and microelements
    292. Comparative evaluation of the antioxidant and anti-Alzheimer’s disease potential of coumestrol and puerarol isolated from pueraria lobata using molecular modeling …
    293. Comparative study on the inhibitory effect of caffeic and chlorogenic acids on key enzymes linked to Alzheimer’s disease and some pro-oxidant induced oxidative …
    294. Comparison of protective effects of four polyphenols on neuropathology and behavior of APP/PS1-21 transgenic mice, a model of Alzheimer’s disease
    295. Comparison of Three Amyloid Assembly Inhibitors: The Sugar scyllo-Inositol, the polyphenol Epigallocatechin Gallate, and the Molecular Tweezer CLR01
    296. Complementary Therapies for Parkinson’s Disease: What’s Promoted, Rationale, Potential Risks and Benefits
    297. Compositional Changes in Anthocyanins, Flavonols, and Ellagitannins in Processed Blackberries
    298. Comprehensive review of mechanisms of pathogenesis involved in Alzheimer’s disease and potential therapeutic strategies
    299. Computational approaches to the investigation of proteins involved in Parkinson’s Disease
    300. Computational modeling of multi-target-directed inhibitors against Alzheimer’s disease
    301. Computer-aided structure-based design of multitarget leads for Alzheimer’s disease
    302. Conjugates of catecholamines with cysteine and GSH in Parkinson’s disease: possible mechanisms of formation involving reactive oxygen species
    303. Conservative iron chelation for Neurodegenerative diseases such as Parkinson’s disease and amyotrophic lateral sclerosis
    304. Considerations for the use of polyphenols as therapies in Neurodegenerative diseases
    305. Consumption of anthocyanin-rich cherry juice for 12 weeks improves memory and cognition in older adults with mild-to-moderate dementia
    306. Consumption of fig fruits grown in Oman can improve memory, anxiety, and learning skills in a transgenic mice model of Alzheimer’s disease
    307. Consumption of polyphenol plants may slow aging and associated diseases
    308. Contribution of Intracellular Non-Haem Iron, NF-kB Activation and Inflammatory Responses to Neurodegeneration in Parkinson’s Disease: Prospects for …
    309. Contribution of Intracellular Non-Haem Iron, NF-kB Activation and Inflammatory Responses to Neurodegeneration in Parkinson’s Disease: Prospects for …
    310. Copper-Catalyzed Oxidative Esterification of 2-Carbonyl Substituted Phenols with Alcohols
    311. Correlation between the polyphenol content and antioxidant effect of Cynara scolymus L. mother tincture
    312. Critical Evaluation of Current Alzheimer′ s Drug Discovery (2018-19) & Futuristic Alzheimer drug model approach
    313. Critical role of microglial NADPH oxidase-derived free radicals in the in vitro MPTP model of Parkinson’s disease
    314. Curcumin and Apigenin–novel and promising therapeutics against chronic neuroinflammation in Alzheimer’s disease
    315. Curcumin and Its Nanoformulations as Therapeutic for Alzheimer’s Disease
    316. Curcumin exposure induces expression of the Parkinson’s disease-associated leucine-rich repeat kinase 2 (LRRK2) in rat mesencephalic cells
    317. Curcumin has potent anti‐amyloidogenic effects for Alzheimer’s β‐amyloid fibrils in vitro
    318. Curcumin interaction with copper and iron suggests one possible mechanism of action in Alzheimer’s disease animal models
    319. Curcumin prevents and ameliorates biochemical and behavioral toxicities of MPTP in C57Bl/6J mice: its potential use in preventing and treating parkinsonism
    320. Curcumin-glucoside, a novel synthetic derivative of curcumin, inhibits α-synuclein oligomer formation: relevance to Parkinson’s disease
    321. Current Alzheimer’s management with berries fruits therapy
    322. CURRENT Alzheimer’s MANAGEMENT WITH DIETARY SEEDS THERAPY
    323. Current and emerging pharmacological targets for the treatment of Alzheimer’s disease
    324. Current and emerging therapeutic targets of Alzheimer’s disease for the design of multi-target directed ligands
    325. Current and investigational drugs for treatment of Alzheimer’s disease
    326. Current concepts on selected plant secondary metabolites with promising inhibitory effects against enzymes linked to Alzheimer’s disease
    327. Current evidence on the effect of dietary polyphenols intake on chronic diseases
    328. Current opinions and perspectives on the role of immune system in the pathogenesis of Parkinson’s disease
    329. Current perspectives and mechanisms of relationship between intestinal microbiota dysfunction and dementia: a review
    330. Current pharmacotherapy and putative disease-modifying therapy for Alzheimer’s disease
    331. Current status of metals as therapeutic targets in Alzheimer’s disease
    332. Cytological profiling of natural product scaffolds libraries for Parkinson’s disease
    333. Cytoprotection by Achyrocline satureioides (Lam) DC and some of its main flavonoids against oxidative stress
    334. Cytoprotective effects of phenolic antioxidants and essential fatty acids in human blood monocyte and neuroblastoma cell lines: Surrogates for neurological damage in …
    335. De B. Acetylcholinesterase inhibitory properties of black tea and its polyphenolic components
    336. Defective insulin signalling, mediated by inflammation, connects obesity to Alzheimer disease; relevant pharmacological therapies and preventive dietary …
    337. dementia IN SURINAME
    338. Dementia, preclinical studies in neurodegeneration and its potential for translational medicine in South America
    339. Design and characterization of enzymatic deglycosylation systems to produce drugs against Alzheimer’s disease
    340. Design and development of novel irreversible GSK-3β inhibitors to address Alzheimer’s disease
    341. Design and Molecular dynamic investigations of 7, 8-Dihydroxyflavone Derivatives as potential neuroprotective Agents Against Alpha-synuclein
    342. Design and Molecular dynamic Investigations of 7, 8-Dihydroxyflavone Derivatives as Potential neuroprotective Agents Against Alpha-synuclein
    343. Design and systhesis of nanoparticles for therapy and imaging of Alzheimer’s disease
    344. Design of Multi-target Directed Ligands as a Modern Approach for the Development of Innovative Drug Candidates for Alzheimer’s Disease
    345. Design, Synthesis and Biological Assessment of Ferulic Acid Derivatives as Inhibitors of β-Amyloid Oligomerization in Alzheimer’s Disease
    346. Design, synthesis and biological evaluation of 3-piperazinecarboxylate sarsasapogenin derivatives as potential multifunctional anti-Alzheimer agents
    347. Design, synthesis and biological evaluation of scutellarein derivatives as potential anti-Alzheimer’s disease candidates based on metabolic mechanism
    348. Design, synthesis and evaluation of 4′-OH-flurbiprofen-chalcone hybrids as potential multifunctional agents for Alzheimer’s disease treatment
    349. Design, synthesis and evaluation of chalcone Mannich base derivatives as multifunctional agents for the potential treatment of Alzheimer’s disease
    350. Designing multi-targeted therapeutics for the treatment of Alzheimer’s disease
    351. Destabilization of Alzheimer’s Aβ42 protofibrils with a novel drug candidate wgx-50 by molecular dynamics simulations
    352. Determination of Flavonoids
    353. Determination of total flavonoid content of different parts of Garcinia cowa
    354. Development and application of nano-flavor-drug carriers in Neurodegenerative diseases
    355. Development and validation of analytical methods for the identification and quantification of phenolic compounds from Euterpe oleracea fruits
    356. Development of a grape seed polyphenolic extract with anti‐oligomeric activity as a novel treatment in progressive supranuclear palsy and other tauopathies
    357. Development of Electrochemical Sensors for the Analysis of Therapeutic Compounds and Proteases related to Alzheimer’s disease
    358. Development of multifunctional molecules as potential therapeutic candidates for Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis in the …
    359. Development of tau aggregation inhibitors for Alzheimer’s disease
    360. Development of technologies for the production of polyphenolic nutraceuticals from muscadine grapes and rabbiteye blueberries
    361. Developments with multi-target drugs for Alzheimer’s disease: an overview of the current discovery approaches
    362. Diabetes and Alzheimer’s disease: can tea phytochemicals play a role in prevention?